Are all cytokine storms the same?
- 8 January 2021
- journal article
- editorial
- Published by Springer Science and Business Media LLC in Cancer Immunology, Immunotherapy
- Vol. 70 (4), 887-892
- https://doi.org/10.1007/s00262-020-02822-2
Abstract
Cytokine release syndrome (CRS) is the result of massive pro-inflammatory cytokine release and imbalance in the absence of adequate immunomodulation from signals such as interleukin (IL)-10, resulting in ongoing inflammation, tissue damage and death if left uncontrolled. Although CRS can result from different pro-inflammatory insults, the treatments proposed are similar, regardless of the phase of response. SARS-CoV-2 causes COVID-19, and CRS has been a defining feature of severe disease. Common approaches to treating CRS in other conditions are now applied to COVID-19 and, although some patients respond, it begs the following questions: (1) are all cytokine storms the same regardless of initiating insult, (2) can treatments be considered equally for all CRS events at any phase of the response, (3) can CRS be predicted based on dynamic acute biomarkers and, (4) should patients with CRS undergo long-term monitoring for secondary effects? The aim of this commentary is not to provide a review of COVID-19 pathophysiology or of cytokine storm, but rather to establish a foundation which could act as a platform to inform treatment approaches to CRS, regardless of cause, and the short- and long-term follow-up which may be necessary for affected patients.Keywords
This publication has 17 references indexed in Scilit:
- A Dynamic Immune Response Shapes COVID-19 ProgressionCell Host & Microbe, 2020
- Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory FailureCell Host & Microbe, 2020
- Gasdermin E–mediated target cell pyroptosis by CAR T cells triggers cytokine release syndromeScience Immunology, 2020
- CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockadeNature Medicine, 2018
- Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cellsNature Medicine, 2018
- Endothelial Activation and Blood–Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T CellsCancer Discovery, 2017
- Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor–modified T-cell therapyBlood, 2017
- Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic LeukemiaCancer Discovery, 2016
- Monocyte-Derived Dendritic Cells Perform Hemophagocytosis to Fine-Tune Excessive Immune ResponsesImmunity, 2013
- Cytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412The New England Journal of Medicine, 2006